0GZX.LSE DiaSorin SpA
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is 0GZX.LSE undervalued?
Graham numberThe Graham number of DiaSorin SpA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DiaSorin SpA fundamental analysis
No fundamental analysis for DiaSorin SpA yet.
DiaSorin SpA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DiaSorin SpA
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV…
Full company profileDiaSorin SpA financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
DiaSorin SpA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 569M | 637M | 669M | 706M | 881M | - | - | - |
| Gross Profit | 389M | 432M | 456M | 489M | 603M | - | - | - |
| Operating Income | 173M | 184M | 205M | 218M | 324M | - | - | - |
| Net Income | 112M | 140M | 158M | 176M | 248M | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | 869M | 946M | 906M | 1.06B | 1.25B | - | - | - |
| Total Liabilities | 206M | 204M | 201M | 215M | 292M | - | - | - |
| Shareholders' Equity | 663M | 741M | 705M | 849M | 955M | - | - | - |
| Cash & Short-term Investments | 130M | 173M | 96.5M | 202M | 340M | - | - | - |
| Total Debt | 23.9M | 102K | 81.0K | 24.5M | 30.5M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 166M | 167M | 210M | 233M | 305M | 401M | 389M | - |
| Capital Expenditure | 37.4M | 42.5M | 33.2M | 37.4M | 42.5M | 68.5M | 53.2M | 0.00 |
| Ratios | ||||||||
| ROE | 17.0% | 18.9% | 22.4% | 20.7% | 26.0% | - | - | - |
| ROA | 12.9% | 14.8% | 17.5% | 16.5% | 19.9% | - | - | - |
| Net Profit Margin | 19.7% | 21.9% | 23.6% | 24.9% | 28.2% | - | - | - |
| Debt to Equity | 0.04x | 0.00x | 0.00x | 0.03x | 0.03x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DiaSorin SpA dividends
DiaSorin SpA has not paid dividends in the last 9 fiscal years.
Who owns DiaSorin SpA
- Insiders 57.56%
- Institutions 14.05%
- Public & others 28.40%
- Free float 15.0M
DiaSorin SpA company profile
- Company name
- DiaSorin SpA
- Ticker
- 0GZX.LSE
- ISIN
- IT0003492391
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 3,260
- Fiscal year end
- December
- Address
- Via Crescentino snc, Saluggia, VC, Italy, 13040
- Phone
- 39 016 1487526
- Website
- int.diasorin.com
About DiaSorin SpA
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
DiaSorin SpA management
10- Mr. Carlo RosaCEO, GM & Executive Director · born 1966
- Dr. Chen Menachem EvenChief Commercial Officer, Senior Corporate VP of Commercial Operations & Executive Director · born 1963
- Mr. Alberto DonatiChief Financial Officer · born 1987
- Mr. Fabrizio Piercarlo BonelliChief Scientific Officer
- Ms. Margherita SacerdotiInvestor Relations & ESG Senior Director · born 1983
- Mr. Ulisse SpadaCorporate VP, Head of the Legal Department, Secretary & General Counsel
- Ms. Amelia ParenteSenior Corporate Vice President of Human Resources
- Mr. Alberto CampaniCEO, GM of Diasorin Italy & VP of Global Immuno Operations
- Mr. Luigi CiccheseSenior Corporate VP of Systems & Engineering
- Ms. Rita MaffeiSenior Corporate VP of Quality, Regulatory & Clinical Affairs